ArticleJAMIA open2026
A computational phenotype for pediatric asthma exacerbations requiring hospitalization using electronic health record data.
Article in JAMIA open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Computational phenotypes can be used to improve patient selection for observational studies. We sought to derive and validate a computational phenotype for pediatric asthma exacerbation requiring hospitalization. Methods: Retrospective cohort study using electronic health record (EHR) data from a single quaternary children's hospital. We used ICD 9 and 10 diagnostic codes and medication data to develop multiple iterations of a computational phenotype. Encounters identified by each phenotype were manually reviewed by expert chart reviewers, and positive predictive value (PPV) was calculated. Sensitivity was obtained by comparison with an established cohort in the Virtual Pediatric Systems (VPS) database. Measurements and main results: Our cohort included 19 015 pediatric encounters from 2014 to 2022 admitted with an indication of asthma. Starting with 3 broad criteria (a diagnostic code for asthma, receipt of albuterol, and receipt of systemic steroids), we iteratively added phenotype criteria to improve the PPV. The initial phenotype using albuterol and systemic steroids had 65% PPV. Restricting the timeframe for receipt to the first 24 h of the encounter and increasing the amount of albuterol used improved the PPV to 85%. Encounters using only dexamethasone or not having a diagnostic code for asthma were tested and found to have low PPV. The final phenotype included the use of >1 nebulized albuterol treatment or continuous albuterol and the use of systemic steroids in the first 24 h of hospitalization, plus a diagnostic code for asthma, and excluded encounters that only used dexamethasone. This phenotype achieved a PPV of 93%. Using this as a reference metric, defining the cohort based only on diagnostic codes had a PPV of 34%. Applying these criteria to the VPS cohort admitted to the intensive care unit yielded a sensitivity of 97%. Conclusions: We created a computational phenotype for pediatric asthma exacerbation requiring hospitalization using structured EHR data elements, which achieved a high positive predictive value and sensitivity. This phenotype can be leveraged for future observational studies in this population, but may require institution-specific adjustments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.